HK1249051A1 - 治疗脑肿瘤的方法 - Google Patents

治疗脑肿瘤的方法 Download PDF

Info

Publication number
HK1249051A1
HK1249051A1 HK18108933.3A HK18108933A HK1249051A1 HK 1249051 A1 HK1249051 A1 HK 1249051A1 HK 18108933 A HK18108933 A HK 18108933A HK 1249051 A1 HK1249051 A1 HK 1249051A1
Authority
HK
Hong Kong
Prior art keywords
treating
brain tumor
administering plinabulin
treatment
disclosed
Prior art date
Application number
HK18108933.3A
Other languages
English (en)
Chinese (zh)
Inventor
Lan Huang
Original Assignee
BeyondSpring Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56880412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1249051(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BeyondSpring Pharmaceuticals Inc. filed Critical BeyondSpring Pharmaceuticals Inc.
Publication of HK1249051A1 publication Critical patent/HK1249051A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)
HK18108933.3A 2015-03-06 2016-03-02 治疗脑肿瘤的方法 HK1249051A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562129623P 2015-03-06 2015-03-06
US201562129623P 2015-03-06
US201562249807P 2015-11-02 2015-11-02
US201562249807P 2015-11-02
PCT/US2016/020396 WO2016144636A1 (en) 2015-03-06 2016-03-02 Method of treating a brain tumor

Publications (1)

Publication Number Publication Date
HK1249051A1 true HK1249051A1 (zh) 2018-10-26

Family

ID=56880412

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18108933.3A HK1249051A1 (zh) 2015-03-06 2016-03-02 治疗脑肿瘤的方法

Country Status (16)

Country Link
US (2) US10076518B2 (enExample)
EP (1) EP3265091A4 (enExample)
JP (2) JP6904570B2 (enExample)
KR (1) KR102623404B1 (enExample)
CN (1) CN107530340B (enExample)
AU (2) AU2016229295B2 (enExample)
BR (1) BR112017018964A2 (enExample)
CL (1) CL2017002242A1 (enExample)
HK (1) HK1249051A1 (enExample)
IL (1) IL254262A0 (enExample)
MX (1) MX385914B (enExample)
MY (1) MY194341A (enExample)
RU (1) RU2728796C2 (enExample)
SG (1) SG11201707128TA (enExample)
WO (1) WO2016144636A1 (enExample)
ZA (1) ZA201706035B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102626155B1 (ko) * 2015-03-06 2024-01-17 비욘드스프링 파마수티컬스, 인코포레이티드. Ras 돌연변이와 관련된 암의 치료 방법
JP6904570B2 (ja) 2015-03-06 2021-07-21 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 脳腫瘍の治療方法
AU2016291708B2 (en) 2015-07-13 2020-12-24 Beyondspring Pharmaceuticals, Inc Plinabulin compositions
EP3413885A4 (en) 2016-02-08 2019-09-18 Beyondspring Pharmaceuticals, Inc. COMPOSITIONS WITH TUCARESOL OR ITS ANALOG
SG11201810872UA (en) 2016-06-06 2019-01-30 Beyondspring Pharmaceuticals Inc Composition and method for reducing neutropenia
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
US11400086B2 (en) * 2017-02-01 2022-08-02 Beyondspring Pharmaceuticals, Inc. Method of reducing chemotherapy-induced neutropenia
JP7350015B2 (ja) * 2018-01-24 2023-09-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリンの投与による血小板減少症を軽減するための組成物および方法
WO2020018700A1 (en) * 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
WO2021150109A1 (en) * 2020-01-22 2021-07-29 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Abt-751 and ionizing radiation
BR112022020595A2 (pt) * 2020-04-10 2023-01-17 Lantern Pharma Inc Métodos hidroxiureametil-acilfulveno para tratamento de câncer do cérebro ou câncer do snc.
EP4274662A4 (en) * 2021-01-08 2024-11-27 Lantern Pharma Inc. Treatment of brain metastases and cns metastases using illudins or hydroxylureamethyl acylfulvene
WO2022216908A1 (en) * 2021-04-09 2022-10-13 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors
CN117860672A (zh) 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法
CN120682197A (zh) * 2024-03-19 2025-09-23 大连万春布林医药有限公司 普那布林的盐晶型

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS509164A (enExample) 1973-05-11 1975-01-30
AU576322B2 (en) 1983-07-22 1988-08-25 Ici Australia Limited Alpha-substituted-alpha-cyanomethyl alcohols
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
JPS6411523A (en) 1987-07-06 1989-01-17 Kawashima Tekko Kk Dish feeder in tableware washing machine
JPH059164A (ja) 1991-07-02 1993-01-19 Sumitomo Chem Co Ltd 光学活性マンデロニトリル誘導体の製造方法
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
DE69320206T2 (de) 1992-11-27 1999-02-11 Napro Biotherapeutics Inc Paclitaxel enthaltende injizierbare zusammensetzung
JPH0725858A (ja) 1993-07-13 1995-01-27 Otsuka Pharmaceut Co Ltd ピペラジン誘導体
GB9402809D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9426224D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
US5891877A (en) 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
JP3131574B2 (ja) 1996-09-04 2001-02-05 新日本製鐵株式会社 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤
US5939098A (en) * 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
MXPA00004919A (es) 1997-11-21 2002-10-17 Euro Celtique Sa 2-aminoacetamidas sustituidas y uso de las mismas.
AU747987B2 (en) 1998-01-29 2002-05-30 Aventis Pharmaceuticals Inc. Method for preparing an N-((aliphatic or aromatic)carbonyl)-2-aminoacetamide compound and a cyclyzed compound
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6069146A (en) 1998-03-25 2000-05-30 The Regents Of The University Of California Halimide, a cytotoxic marine natural product, and derivatives thereof
US6333323B1 (en) 1998-03-26 2001-12-25 Shionogi & Co., Ltd. Indole derivatives with antiviral activity
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
FR2784988B1 (fr) 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7026322B2 (en) 1998-11-12 2006-04-11 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
US6358957B1 (en) 1998-11-12 2002-03-19 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
EP2360254A1 (en) 1999-08-23 2011-08-24 Dana-Farber Cancer Institute, Inc. Assays for screening anti-pd-1 antibodies and uses thereof
DE60033293D1 (de) 1999-08-23 2007-03-22 Dana Farber Cancer Inst Inc Neue b7-4 moleküle und deren verwendungen
AU784634B2 (en) 1999-11-30 2006-05-18 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
NZ519989A (en) 2000-01-18 2004-05-28 Nereus Pharmaceuticals Inc Cell division inhibitors and process for producing the same
EP1282609B1 (en) 2000-05-09 2008-12-17 AngioRx Corporation Piperazinedione compounds
US6583143B2 (en) 2000-12-28 2003-06-24 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US7064201B2 (en) 2002-08-02 2006-06-20 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
BRPI0506655A (pt) * 2004-02-04 2007-05-08 Nereus Pharmaceuticals Inc dehidrofenilahistinas e seus análogos, e sìntese de dehidrofenilahistinas e seus análogos
DE202004018940U1 (de) 2004-12-07 2006-04-13 Asf Verwaltungs Gmbh Druckverschluß, Druckverschlußband und wiederverschließbarer Beutel
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
RS54271B1 (sr) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
EP2338518A1 (en) * 2006-01-18 2011-06-29 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
CN101909693A (zh) 2008-01-08 2010-12-08 百时美施贵宝公司 用于治疗增殖性疾病的抗-ctla4抗体与微管蛋白调节剂的组合
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
HRP20170908T1 (hr) 2008-12-09 2017-09-22 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
WO2010114922A1 (en) * 2009-03-31 2010-10-07 Agios Pharmaceuticals, Inc. Methods of treating cancer having an aberrant egfr or kras genotype
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
ES2543280T3 (es) 2009-08-10 2015-08-17 Board Of Regents, The University Of Texas System Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
EP2571577A1 (en) 2010-05-17 2013-03-27 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
CA2799653A1 (en) * 2010-06-04 2011-12-08 Bertrand Leblond Substituted isoquinolines and their use as tubulin polymerization inhibitors
JP2012033526A (ja) 2010-07-28 2012-02-16 Fuji Electric Co Ltd 薄膜太陽電池およびその製造方法
WO2012035436A1 (en) 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
TWI386203B (zh) 2011-01-07 2013-02-21 Univ China Medical 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
AU2013204313C1 (en) * 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
CA2905418C (en) 2013-03-13 2023-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
JP6526627B2 (ja) 2013-04-24 2019-06-05 テル ハショメール メディカル リサーチ インフラストラクチャー アンド サービシズ リミテッド 組織解析用の磁気共鳴マップ
CA2926771C (en) 2013-10-11 2022-07-05 Beyondspring Pharmaceuticals, Inc. Cancer treatment with combination of plinabulin and taxane
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
US20180028531A1 (en) 2015-02-12 2018-02-01 BeyondSpring Phamaceuticals, Inc. Use of plinabulin in combination with immune checkpoint inhibitors
KR102626155B1 (ko) 2015-03-06 2024-01-17 비욘드스프링 파마수티컬스, 인코포레이티드. Ras 돌연변이와 관련된 암의 치료 방법
JP6904570B2 (ja) 2015-03-06 2021-07-21 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 脳腫瘍の治療方法
AU2016291708B2 (en) 2015-07-13 2020-12-24 Beyondspring Pharmaceuticals, Inc Plinabulin compositions
EP3413885A4 (en) 2016-02-08 2019-09-18 Beyondspring Pharmaceuticals, Inc. COMPOSITIONS WITH TUCARESOL OR ITS ANALOG
SG11201810872UA (en) 2016-06-06 2019-01-30 Beyondspring Pharmaceuticals Inc Composition and method for reducing neutropenia
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
US11400086B2 (en) 2017-02-01 2022-08-02 Beyondspring Pharmaceuticals, Inc. Method of reducing chemotherapy-induced neutropenia
CA3056077A1 (en) 2017-03-13 2018-09-20 Beyondspring Pharmaceuticals, Inc. Compositions of plinabulin and use thereof

Also Published As

Publication number Publication date
CN107530340A (zh) 2018-01-02
MX385914B (es) 2025-03-18
RU2017131448A (ru) 2019-04-08
MY194341A (en) 2022-11-29
AU2021254549A1 (en) 2021-11-18
CN107530340B (zh) 2021-06-08
US20180042921A1 (en) 2018-02-15
EP3265091A1 (en) 2018-01-10
JP2018507245A (ja) 2018-03-15
CA2978679A1 (en) 2016-09-15
JP6904570B2 (ja) 2021-07-21
JP2021091695A (ja) 2021-06-17
IL254262A0 (en) 2017-10-31
KR20170123642A (ko) 2017-11-08
KR102623404B1 (ko) 2024-01-11
SG11201707128TA (en) 2017-09-28
BR112017018964A2 (pt) 2018-05-22
MX2017011375A (es) 2018-01-23
US10357491B2 (en) 2019-07-23
AU2021254549B2 (en) 2024-10-24
US20190000841A1 (en) 2019-01-03
JP7264331B2 (ja) 2023-04-25
RU2728796C2 (ru) 2020-07-31
CL2017002242A1 (es) 2018-04-02
HK1250007A1 (zh) 2018-11-23
WO2016144636A1 (en) 2016-09-15
US10076518B2 (en) 2018-09-18
EP3265091A4 (en) 2018-08-01
AU2016229295B2 (en) 2021-11-04
AU2016229295A1 (en) 2017-09-28
RU2017131448A3 (enExample) 2019-08-20
ZA201706035B (en) 2019-12-18

Similar Documents

Publication Publication Date Title
HK1249051A1 (zh) 治疗脑肿瘤的方法
IL283838A (en) Method of treating cancer with a cancer therapy in combination with another therapeutic agent
IL288341B (en) Targeted ligands for medicinal compounds, methods for their preparation and uses thereof
HK1249052A1 (zh) 治疗与ras突变相关的癌症的方法
IL272444A (en) Compounds, their salts and methods for treating diseases
PH12015502075A1 (en) Treatment of cataplexy
IL240060A0 (en) Treatment involving antibodies against claudin 2. 18 for the treatment of cancer
EP3240612A4 (en) Methods of treating retinal diseases
EA201891340A1 (ru) Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек
ZA201903873B (en) Methods of treating cochlear synaptopathy
NZ722600A (en) Methods of treating mild brain injury
ZA201705877B (en) Method of treating diseases
IL255506A (en) A method for treating a neurological disease
EP3558301A4 (en) METHOD FOR TREATING GLIOBLASTOMA MULTIFORME WITH IBUDILAST
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
EP2991620A4 (en) Method of treating disease by auricular anesthesia of cranial nerves
TW201613639A (en) Methods for treating cardiovascular diseases
EP3182992A4 (en) Methods of treating mild brain injury
PL2976360T3 (pl) Terapia obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu złośliwego
IL253847A0 (en) Methods of treating diseases
SG10201802808SA (en) Method of treating ocular disorders
EP3181562A4 (en) Phenylaminopyrimidine-derived compounds, method for producing the same, use of said compounds for the treatment of cancer, and treatment methods
HK40001292A (en) A method for targeted intraprostatic administration of prx302 for treatment of prostate cancer
HK1258790A1 (en) Methods for treating cardiac injury